A drug called SR419, developed by the Chinese Academy of Sciences (CAS) and Shanghai SIMR Biotechnology Co., Ltd. has entered clinical trials in China, reports the Ministry of Science and Technology.

Reported in Xinhuanet, the pain reliever was developed to address neuropathic pain.

A Growing Problem in China

Incidents of neuropathic pain grow in China, especially among the elderly—at 49.8% and more than 50% with cancer patients.  Conventional painkillers don’t work well.

Enter Research Zhang Xu

A CAS clinical researcher, Zhang Xu, has studied neuropathic pain for nearly 30 years. The Shanghai SIMR Biotechnology company adopted Dr. Xu’s research as the basis for SR419. It represents China’s first neuropharmaceutical research and development platform.

Results to Date: Targeting Pain Reduction

Thus far, preclinical data reveals positive results are reported. The Candidate drug has proven effective in relieving chronic pain caused by nerve damage while reducing side effects. SR419 has a strong analgesic drug for specific targets. It has the potential to become the world’s first analgesic drug for specific targets.

Phase I Study in Australia

A Phase I study is presently being conducted in Australia. Sponsored by Shanghai affiliate in Australia [SIMR (Austrailia) Biotech Pty Ltd], the study is being conducted by contract research organization Syneos Health. The Phase I study has been designed to evaluate the safety, tolerability, and PK of SR419 in healthy volunteers. The study is conducted in three parts including A) single-dose-escalation study of SR419; B) repeated dose escalation study of SR419 and C) repeated dose study of SR419.

The Australian clinical research site is Peth-based Linear Clinical Research. The principal investigator is Dr. Lara Hatchuel. With a target of 84 participants, the study is scheduled to end March 2020.

Investigator Profile: Zhang Xu

The inventor of this drug target, Zhang Xu, is a Chinese neuroscientist with the Chinese Academy of Sciences (CAS) and the World Academy of Sciences. He is a research professor at the CAS Institute of Neuroscience (ION) and serves as Vice President of the Shanghai Branch of the CAS. Zhang studied at the Fourth Military Medical University and the Karolinska Institute (Sweden).

Shanghai SIMR Biotechnology

Known as SIMR, they are an innovation-oriented biopharmaceutical company dedicated to new drugs for pain and other nervous system diseases. Founded in 2014, they have developed robust capability in discovery and clinical development. Between 2016 and 2018, they completed a total funding rounds in the tens of millions from Chinese investors. They have developed a growing pipeline.

Call to Action: Interested in tracking this new pain medication? Sign up for the TrialSite Newsletter as SR419 is tracked by our monitoring system.

Source: Xinhua Net

Pin It on Pinterest